The use of TP-03 for was well-tolerated and showed promising efficacy in the treatment of Demodex Blepharitis, according to results from a Phase 2 trial presented at the ARVO 2020 Virtual Meeting.
In the Phase 2a Mars Study, the use of TP-03 for 4 weeks in 15 patients with Demodex Blepharitis showed promising efficacy, with treatment effects lasting for ≥ 90 days. Beginning at day 14 there was a statistically significant decreases in mean collarette score and mite density which continued throughout the 90-day study period.
“We are excited that TP-03 has shown rapid, complete, and durable efficacy across both measures with a tolerable and safe eyedrop,” said Tarsus CEO Bobak Azamian, MD, PhD in a press release. “These results are the beginning of a strong, consistent data set we are generating with TP-03 to treat the underlying cause of Demodex Blepharitis and other conditions.”
Read the full press release here.